SEC 8-K
SEC 8-K: Item 5.02, 5.07, 9.01
Official SEC filing update. Items: 5.02, 5.07, 9.01.
Item 5.02, 5.07, 9.01Accession 0001193125-26-276688
EyePoint, Inc. (EYPT) Financials, Dividends & Stock Info
Explore comprehensive financial data for EyePoint, Inc., provided completely free. Analyze revenue, net income, profit margins, dividend history, and key financial ratios to make informed investment decisions.
Data as of (571 days ago)|Source: SEC EDGAR
The information on this page is for informational purposes only and does not constitute investment advice, financial advice, or any recommendation. Billiver does not recommend buying, selling, or holding any security. Past performance is not indicative of future results.
Data may be delayed and accuracy is not guaranteed. All investment decisions are solely your responsibility. Verify information independently and consult a qualified financial advisor before investing. About · Methodology
EYPTHealth Care
EyePoint, Inc. (EYPT) is a life sciences tools & services company. The company reports annual revenue of $43M and net loss of $131M.
EyePoint, Inc. Key Financials(TTM Est.)
Revenue (TTM)↓ 31.8%
$43.3M
Net Income (TTM)↓ 227.7%
$-130.9M
Data from SEC EDGAR filings. TTM = Trailing Twelve Months.
EyePoint, Inc. Financial Health ScoreFY2025
0/100
Weak financial health; requires careful evaluation
-8 pts YoYProfitability15Liquidity70Growth10Cash Flow15Efficiency18
This Financial Health Score is a proprietary metric calculated from SEC EDGAR filings for educational and informational purposes only. It does not constitute investment advice or a recommendation to buy or sell any security. Results vary significantly by industry. Conduct your own research before making investment decisions.
Data Highlights
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -1.77 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
EyePoint, Inc. Official SEC Updates
Official filing updates from SEC EDGAR. Billiver stores internal evidence snapshots for verification, but this page links to the SEC source instead of republishing full filing text.
Open SEC filing
SEC 8-K
SEC 8-K: Item 8.01, 9.01
Official SEC filing update. Items: 8.01, 9.01.
Item 8.01, 9.01Accession 0001193125-26-222750
SEC 10-Q
SEC 10-Q
Official SEC filing update.
10-QAccession 0001193125-26-211870
SEC 8-K
SEC 8-K: Item 2.02, 9.01
Official SEC filing update. Items: 2.02, 9.01.
Item 2.02, 9.01Accession 0001193125-26-207537
SEC DEF 14A
SEC DEF 14A
Official SEC filing update.
DEF 14AAccession 0001193125-26-182035
Source: SEC EDGAR · 5 filings
Informational only. Not investment advice.
5-Year Revenue & Net Income Trend
Chart shows fiscal year data from SEC EDGAR filings. Hover over data points for details.
As of FY2025 · SEC 10-K · Updated Jul 2, 2026
About EyePoint, Inc.
- Industry
- Life Sciences Tools & Services
Valuation
Valuation Data UnavailablePrice-based valuation metrics (P/E, P/B) require real-time stock price data which is not included in SEC filings.
Benjamin Graham: Graham recommended P/E ratio not exceed 15 for reasonable valuation. Understanding valuation metrics
Profitability
Profitability Data Under ReviewRevenue (TTM)*$43M
Net Income (TTM)*-$131M (Loss)
* Some quarterly data is missing. Values are calculated based on annual report figures.
Profitability metrics are being verified. Some SEC filing data may require additional validation.
Warren Buffett: Buffett looks for consistent ROE above 20% as a sign of competitive advantage. How to evaluate profitability
Financial Health
Balance Sheet Data LimitedInsufficient data to assess financial health.
Peter Lynch: Lynch: normal balance sheet has 75% equity, 25% debt. Understanding financial health
Dividend
Dividend Data UnavailableDividend yield data is not available from SEC filings. Check the company's investor relations page for dividend information.
As of FY2025 · SEC 10-K · Updated Jul 2, 2026
EyePoint, Inc. 10-Year Revenue, Profit & Cash Flow History
Annual Financials
FY2025 - FY2016| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $31.4M(-31.8%) | $46.0M(+11.1%) | $41.4M(0.0%) | $41.4M(+20.2%) | $34.4M(+69.1%) | $20.4M(+170.1%) | $7.5M(+154.6%) | $3.0M(+401.9%) | $590,000(-63.6%) | $1.6M(-24.4%) |
| Net Income | $-231,962,000(-227.7%) | $-70,795,000(+30.8%) | $-102,254,000(0.0%) | $-102,254,000(-125.3%) | $-45,394,000(+20.1%) | $-56,793,000(-207.2%) | $-18,485,000(+65.2%) | $-53,171,000(-187.6%) | $-18,485,000(+14.2%) | $-21,547,000(-81.1%) |
| Total Assets | $364.0M | $418.5M | $355.2M | $180.4M | $263.4M | $91.7M | $73.0M | $78.2M | $18.7M | $31.6M |
| Total Debt | - | - | - | $30.0M | $36.6M | $38.0M | $47.2M | $17.6M | $0 | - |
| Total Equity | $306.1M | $266.3M | $96.4M | $96.4M | $18.5M | $8.3M | $37.6M | $37.6M | $13.3M | $20.9M |
| Profit Margin | -739.4% | -153.8% | -247.0% | -247.0% | -131.8% | -278.9% | -245.2% | -1795.7% | -3133.1% | -1330.1% |
| ROE | -75.8% | -26.6% | -106.1% | -106.1% | -244.8% | -681.8% | -49.1% | -141.3% | -138.6% | -103.2% |
| ROA | -63.7% | -16.9% | -28.8% | -56.7% | -17.2% | -61.9% | -25.3% | -68.0% | -99.0% | -68.2% |
Quarterly Financials
Last 8 quarters| Metric | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $24.5M | $966,000 | $5.3M | $24.5M | $10.5M | $9.5M | $11.7M | $15.2M |
| Net Income | $-45,195,000 | $-59,732,000 | $-59,426,000 | $-45,195,000 | $-29,361,000 | $-30,826,000 | $-29,284,000 | $-12,612,000 |
| Total Assets | $364.0M | $251.7M | $301.1M | $362.6M | $300.9M | $324.2M | $329.2M | $160.0M |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026
Insider Trading
Loading chart...
Loading transactions...
Source: SEC EDGAR Form 4 filings. Only purchase (P) and sale (S) transactions shown.
EyePoint, Inc. Free Cash Flow & Dividend Coverage
Free Cash Flow
-$243.4M
FY2025
FCF Margin
-775.8%
FCF / Revenue
Operating Cash Flow
-$240.1M
Cash from operations
FCF / Net Income
1.05x
Quality earnings
Cash Flow History
FY2016 - FY2025| Metric | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating CF | -$16.3M | -$20.5M | -$21.9M | -$20.5M | -$56.7M | -$14.4M | -$65.0M | -$65.0M | $1.9M | -$240.1M |
| CapEx | -$113,000 | -$147,000 | -$108,000 | -$147,000 | -$213,000 | -$362,000 | -$2.1M | -$2.1M | -$3.5M | -$3.3M |
| Free Cash Flow | -$16.4M | -$20.6M | -$22.0M | -$20.6M | -$56.9M | -$14.8M | -$67.2M | -$67.2M | -$1.6M | -$243.4M |
| FCF Margin | -1014.1% | -3497.8% | -743.5% | -273.7% | -279.5% | -43.0% | -162.2% | -162.2% | -3.5% | -775.8% |
Source: SEC EDGAR 10-K filings. FCF = Operating Cash Flow - Capital Expenditures. Free cash flow guide
As of FY2025 · SEC 10-K · Updated Jul 2, 2026
EyePoint, Inc. Risk Factors
Company-disclosed SEC risk factors
Risk factors are disclosed by the company in its SEC Form 10-K, Item 1A. Billiver does not classify or summarize company-specific legal, operational, financial, or market risks here.
Sector context: Health Care. This is not a Billiver risk assessment for EYPT.
Source note: the SEC Form 10-K includes Item 1A, "Risk Factors." The full risk-factor text should be read from the company’s own SEC filing.
EyePoint, Inc. FAQ
What is EyePoint, Inc.'s annual revenue?
EyePoint, Inc. (EYPT) reported $43 million in trailing twelve-month (TTM) revenue. This financial data is compiled from SEC EDGAR 10-K filings.
Does EyePoint, Inc. pay dividends?
No, EyePoint, Inc. (EYPT) does not currently pay dividends to shareholders.
What is EyePoint, Inc.'s financial health score?
EyePoint, Inc. has a financial health score of 25/100 (Grade: F), evaluating profitability, solvency, liquidity, and growth based on SEC EDGAR data.
How many years of EyePoint, Inc. financial data are available?
10 years of financial data are available for EyePoint, Inc. from FY2016 to FY2025. All figures are compiled from SEC EDGAR 10-K filings.